IR

Isofol Medical AB (publ) publishes annual report and corporate governance report for 2023

GOTHENBURG, Sweden, April 16, 2024 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), today announced that the company’s annual report and corporate governance report for the financial year 2023 are now available, in Swedish, on the company’s website, www.isofolmedical.com. The information in the press release is intended for investors. For further information, please contactIsofol Medical […]

Isofol Medical AB (publ) publishes annual report and corporate governance report for 2023 Read More »

Notice to attend the Annual General Meeting held on May 8, 2024 in Isofol Medical AB (publ)

GOTHENBURG, Sweden, April 5, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites the shareholders of Isofol Medical AB (publ), Reg. No. 556759-8064 based in Gothenburg, to the Annual General Meeting on Wednesday, May 8, 2024. The information in the press release is intended for investors. The shareholders in Isofol Medical AB (publ),

Notice to attend the Annual General Meeting held on May 8, 2024 in Isofol Medical AB (publ) Read More »

Isofol’s Japanese partner Solasia intensifies its commitment to the clinical development of arfolitixorin

GOTHENBURG, Sweden, March 19, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol”), today announces that the company’s collaboration partner, the Japanese pharmaceutical company Solasia Pharma K.K. (“Solasia”), has confirmed its continued strong commitment in the development of arfolitixorin. Solasia will contribute with its expertise and participate in defining the detailed design of the

Isofol’s Japanese partner Solasia intensifies its commitment to the clinical development of arfolitixorin Read More »

Isofol presents a clinical development plan for arfolitixorin

GOTHENBURG, Sweden, March 19, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol”), today presents the company’s continued strategy and clinical development program for the drug candidate arfolitixorin. The board and management, together with external experts, have evaluated the available data for arfolitixorin and decided to conduct a clinical phase I/II study to document

Isofol presents a clinical development plan for arfolitixorin Read More »

Isofol Medical AB (publ) publishes year-end report, January – December 2023

GOTHENBURG, Sweden, February 20, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s year-end report for January – December 2023 is now available on the company’s website, www.isofolmedical.com. The information in the press release is intended for investors. Fourth quarter, October – December 2023 Net revenue amounted to kSEK 0

Isofol Medical AB (publ) publishes year-end report, January – December 2023 Read More »

Isofol’s Board of Directors decides to initiate the planning of clinical studies and will announce a strategic development plan on March 19

GOTHENBURG, Sweden, February 14, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), has been engaged in intensive strategy work since the new Board of Directors and management took office in January. The Board of Directors has decided today to prepare a new development program for arfolitixorin, with the goal of initiating new clinical studies

Isofol’s Board of Directors decides to initiate the planning of clinical studies and will announce a strategic development plan on March 19 Read More »

Isofol appoints Magnus Hurst as new Chief Financial Officer

GOTHENBURG, Sweden, January 10, 2024 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today announces that the company has appointed Magnus Hurst as new Chief Financial Officer. He has broad financial experience and takes up the position with immediate effect. The information in the press release is intended for investors. Magnus Hurst has long experience

Isofol appoints Magnus Hurst as new Chief Financial Officer Read More »

Isofol appoints Petter Segelman Lindqvist as new CEO

GOTHENBURG, Sweden, January 9, 2024 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announces today that the company’s Board of Directors has appointed Petter Segelman Lindqvist as new Chief Executive Officer. He has extensive experience from leading roles in several international pharmaceutical companies and takes up the position with immediate effect. The information in the

Isofol appoints Petter Segelman Lindqvist as new CEO Read More »

Bulletin from extraordinary general meeting in Isofol Medical AB (publ) held on January 4, 2024

Today on January 4, 2024 in Gothenburg, Sweden – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), held its extraordinary general meeting (“EGM”) at which the following principal resolutions were passed. The information in the press release is intended for investors. Election of members and chairman of the board, determination of fees to the board of

Bulletin from extraordinary general meeting in Isofol Medical AB (publ) held on January 4, 2024 Read More »

Isofol presents additional results from laboratory tests with arfolitixorin showing supplementary effects

GOTHENBURG, Sweden, December 28, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announces today that the company has received additional results from the laboratory tests conducted with arfolitixorin ahead of a potential decision on the drug candidate’s continued clinical development. The results show interesting supplementary effects of arfolitixorin in two of a total of

Isofol presents additional results from laboratory tests with arfolitixorin showing supplementary effects Read More »

Scroll to Top